Compare ADMA Biologics Inc (ADMA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs TKO Group Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.16 (market cap $2.13B), while TKO Group Holdings Inc trades at $192.91 (market cap $14.51B). The key difference: TKO Group Holdings Inc is far larger — about 6.8× ADMA Biologics Inc's market cap, and TKO Group Holdings Inc pays a 1.61% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TKO | |
|---|---|---|
Market Cap | $2.13B | $14.51B |
Sector | Health | Technology |
52-Week High | $20.38 | $224.96 |
52-Week Low | $7.60 | $155.61 |
Enterprise Value | $2.20B | $18.69B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
TKO trades at $192.30, down 1.09% today, with a bearish technical signal. The stock shows mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $4.74B in 2025, with net income of $195.40M, though high P/E of 71.49 suggests premium valuation. Recent news includes a successful WWE-UFC doubleheader and an $800M share repurchase, indicating strong operational momentum.
Outlook remains positive with 84% analyst buy ratings and a $234 consensus target, but risks include earnings volatility and competitive pressures. The stock offers growth potential through live event demand and media deals, yet investors should monitor margin sustainability amid high valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
